M&A Deal Summary

Conmed Acquires Biorez

On August 1, 2022, Conmed acquired medical products company Biorez for 85M USD

Acquisition Highlights
  • This is Conmed’s 9th transaction in the Medical Products sector.
  • This is Conmed’s 5th largest (disclosed) transaction.
  • This is Conmed’s 8th transaction in the United States.
  • This is Conmed’s 2nd transaction in Connecticut.

M&A Deal Summary

Date 2022-08-01
Target Biorez
Sector Medical Products
Buyer(s) Conmed
Deal Type Add-on Acquisition
Deal Value 85M USD

Target

Biorez

New Haven, Connecticut, United States
Biorez is a medical device start-up focused on advancing the healing of soft tissues using its proprietary BioBrace Implant technology. Biorez was founded in 2016 and is based in New Haven, Connecticut.

Search 200,500 Deals Now

SEARCH BY

  • Buyer Type (PE or Strategic)
  • Deal Size ($10M to $10B+)
  • Sector (60 Sectors)
  • Deal Type
  • Geography
  • & More

Try For Free 7-Day Free Trial

Buyer(S) 1

Buyer

Conmed

Largo, Florida, United States

Category Company
Founded 1970
Sector Medical Products
Employees4,100
Revenue 1.2B USD (2023)
DESCRIPTION

Conmed is a medical technology company with an emphasis on surgical devices and equipment for minimally invasive procedures and monitoring. The Company’s products are used by surgeons and physicians in a variety of specialties including orthopedics, general surgery, gynecology, neurosurgery and gastroenterology. Conmed was founded in 1970 and is based in Largo, Florida.


DEAL STATS #
Overall 9 of 9
Sector (Medical Products) 9 of 9
Type (Add-on Acquisition) 6 of 6
State (Connecticut) 2 of 2
Country (United States) 8 of 8
Year (2022) 2 of 2
Size (of disclosed) 5 of 7
PREVIOUS DEAL
DATE TARGET DEAL TYPE VALUE
2022-05-04 In2Bones

Memphis, Tennessee, United States

In2Bones is a global developer manufacturer and distributor of medical devices for the treatment of disorders and injuries of the upper (hand, wrist, elbow) and lower (foot and ankle) extremities. In2Bones is based in Memphis, Tennessee.

Buy $145M